Efficacy, mechanism, and safety of melatonin‐loaded on thermosensitive nanogels for rabbit VX2 tumor embolization: A novel design

Abstract

Transarterial chemoembolization (TACE) has been widely used for hepatocellular carcinoma. Reducing hypoxia in the tumor microenvironment after TACE remains a challenge as tumor progression is common in post‐TACE patients due to the hypoxic tumor microenvironment. In this study, melatonin loaded on p(N‐isopropyl‐acrylamide‐co‐butyl methylacrylate) (PIB‐M) was used for tumor embolism. Two types of human hepatoma cell lines were used to explore the mechanism by which melatonin prevents the growth and metastasis of cancer cells in vitro. A VX2 rabbit tumor model was used to evaluate the efficacy, mechanism, and safety of PIB‐M in vivo. We found that under hypoxic condition, melatonin could inhibit tumor cell proliferation and migration by targeting hypoxia inducible factor‐1α (HIF‐1α) and vascular endothelial growth factor A (VEGF‐A) in vitro. In vivo, PIB‐M inhibited tumor growth and metastasis in rabbit VX2 tumors by promoting apoptosis of tumor cells and targeting related angiogenic proteins and vascular permeability proteins. A high concentration of melatonin in the PIB‐M group could be maintained in tumor tissue for 72 h after embolization. The liver and kidney functions were most damaged on the first day but recovered to normal on the seventh day after embolization in the PIB‐M group. This novel method may open avenues for reduction of tumor growth and metastasis after TACE and is efficacy and safety, which may be used for treatment for other solid tumors and clinical translation.